NOV 22, 2020 11:20 AM PST

Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD

WRITTEN BY: Annie Lennon

Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescription are linked to an increased risk of death and hospitalization in older patients with chronic obstructive pulmonary disease (COPD). 

For the study, the researchers looked at data from over 4,000 people with COPD in Ontario aged over 66 between 2006 and 2016. The patients were divided into two groups. One group used dronabinol or nabilone, synthetic cannabinoids with a similar chemical structure to THC often prescribed to treat COPD symptoms such as pain, difficulties falling asleep, and breathlessness. Meanwhile, the other group did not use these cannabinoids. 

In the end, the researchers found that while patients who used either cannabinoid were no more likely to be hospitalized for COPD or pneumonia than those in the other group, they were more likely to die of any cause. This was especially true for those who received high doses. All in all, these patients were 178% more likely to be hospitalized for COPD and pneumonia and 231% more likely to die of any cause. 

“Our study results do not mean that cannabinoid drugs should be never used among older adults with COPD,” says Dr. Nicholas Vozoris, lead author of the study. “Rather, our findings should be incorporated by patients and physicians into prescribing decision-making.”

While the researchers say that their findings show a negative association between older adults with COPD and synthetic cannabinoids, further research is needed to confirm their results. Nevertheless, as older adults are increasingly using cannabinoid-based drugs to treat COPD, the researchers say care should be taken when prescribing the drugs and for patients and physicians alike to have a clear understanding of their potential side effects. 

 

Sources: BMJMarijuana Business Daily

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 03, 2020
Cannabis Sciences
Cannabis Compound Prevents Colon Cancer in Mice
OCT 03, 2020
Cannabis Compound Prevents Colon Cancer in Mice
Second only to skin cancer, colon cancer is the most common cancer diagnosed in both men and women in the US. Now, resea ...
OCT 14, 2020
Health & Medicine
Sanobiotec Produces Reliable THCV
OCT 14, 2020
Sanobiotec Produces Reliable THCV
Lithuania-based bio Sanobiotec has joined a band of biotech companies moving into the synthetic cannabinoid market and a ...
OCT 29, 2020
Cannabis Sciences
Hemp 10 Years from Now
OCT 29, 2020
Hemp 10 Years from Now
The hemp industry has experienced major growth in recent years, largely due to legalization in many US states. Today, th ...
NOV 15, 2020
Cannabis Sciences
Cannabis Almost 25% Stronger Now than 50 Years Ago
NOV 15, 2020
Cannabis Almost 25% Stronger Now than 50 Years Ago
Researchers from the University of Bath in England have found that cannabis has increased in strength by up to 25% in th ...
NOV 22, 2020
Cannabis Sciences
Public Believes CBD is Cure-All Despite Lack of Evidence
NOV 22, 2020
Public Believes CBD is Cure-All Despite Lack of Evidence
Many people think that cannabidiol (CBD), a non-psychoactive compound in cannabis, can reduce symptoms from various cond ...
JAN 21, 2021
Health & Medicine
More Evidence Cannabis Can Calm a Cytokine Storm
JAN 21, 2021
More Evidence Cannabis Can Calm a Cytokine Storm
A new study out of Canada lends further evidence to the idea that cannabis components may help to calm the cytokine stor ...
Loading Comments...